« Return to News | CROs/Service Providers

PPD Plans for Single-Digit Growth

Wednesday, January 20, 2010 09:57 AM

PPD expects limited revenue growth in 2010, according to the contract research organization’s (CRO’s) 2010 guidance announced last night.

The company anticipates net revenue for the full year 2010 to be in the range of $1.31billion to $1.43 billion with earnings per share (EPS) to be in the range of $1.00 to $1.12. PPD has not yet released its final year-end results for 2009, but, as of the end of the third quarter, PPD’s expected revenue for 2009 was $1.29 billion to $1.315 billion with EPS in the range of $1.38 to $1.40. The drop in EPS in 2010 is a result of PPD’s plans to spin off its compound partnering business from CRO operations. Once the spin-off is complete—by mid-year, PPD said—the two businesses will operate as two independent public companies. Only the CRO business will carry the PPD name.

"We have entered 2010 with clear objectives to restore growth in our business and to create long-term value for our shareholders," said PPD CEO David Grange in a statement. "Strengthening our business models, establishing innovative partnerships, and enhancing our global capacity remain key priorities for us in 2010. As we continue to align our business for success, we will continue to invest strategically in our global future. "

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.